Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
Hagop M KantarjianSusan BranfordMassimo BrecciaJorge E CortesFadi G HaddadAndreas HochhausTimothy HughesGhayas C IssaElias J JabbourFranck E NicoliniKoiji SasakiFrancois Xavier-MahonPublished in: Leukemia (2024)